companies that make glp-1 drugs The future of in healthcare: Vital's role in enhancing metabolic treatment programs The Disruptive Power of Weight

During 2024 and 2025, the GLP-1 class was increasingly defined by expanded use cases and approvals, with existing drugs gaining indications including cardiovascular risk, sleep apnea and kidney disease

A possible side effect of taking insulin is low blood glucose (hypoglycemia)

[DOI] [PubMed] [Google Scholar] 39.Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B

ChengCKLuoJYLauCWChoWCNgCFMaRCWet al

It's approved to reduce risk of cardiovascular death and hospitalization for heart failure in adults

After Ozempic, the market is moving toward obesity-specific injectables, oral GLP-1 drugs, dual agonists, triple agonists, amylin combinations, and cardiometabolic platform therapies